Drugs / Peginterferon
Peginterferon
also known as
PEG-IFNα-2a · PegIFN · peginterferon alfa 2a · pegylated interferon α-2a · Pegylated Interferon-alpha
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00718172 | Jul 2008 → Aug 2014 | chronic hepatitis C virus infection | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01959633 | Apr 2014 → Mar 2018 | melanoma | Fondazione Melanoma Onlus | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00735969 | Aug 2008 → Jun 2013 | chronic hepatitis C virus infection | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT00146913 | Mar 2004 → ? | chronic myeloid leukemia | Hospices Civils de Lyon | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00301509 | Jan 2002 → Dec 2005 | cirrhosis of liver | Casa Sollievo della Sofferenza IRCCS | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT01369199 | May 2012 → Feb 2017 | chronic hepatitis B virus infection | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Terminated | No outcome recorded |
| Phase 3 | NCT00296972 | Jul 2005 → Apr 2007 | HIV infectious disease, chronic hepatitis C virus infection | University Health Network, Toronto | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT00732641 | Dec 2000 → Nov 2010 | plasma cell myeloma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01731301 | Jan 2013 → Jan 2014 | chronic hepatitis C virus infection, end stage renal failure | Liver Institute of Virginia | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00249574 | Jun 2003 → Mar 2004 | hepatitis C virus infection, heroin dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Comparator or background therapy14 trials | ||||||
| Phase 1 | NCT02781753 Comparator | Apr → Aug 2016 | — | Tianjin SinoBiotech Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01901198 Comparator | Apr → Sep 2013 | — | Beijing Bio-Fortune Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01704521 Comparator | Dec 2012 → Oct 2014 | chronic hepatitis C virus infection, hemophilia | Kenneth Sherman | Completed | No outcome recorded |
| Phase 1 | NCT01547312 Background | May → Nov 2012 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 1 | NCT00251199 Background | Oct 2005 → Mar 2006 | hepatitis C virus infection | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 2 | NCT02216045 Background | Jun 2014 → Feb 2015 | chronic hepatitis C virus infection | Mashhad University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01528735 Background | Feb 2012 → Aug 2013 | chronic hepatitis C virus infection | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00978497 Background | Sep 2009 → Apr 2010 | hepatitis C virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00665353 Background | Mar 2009 → May 2011 | — | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 2 | NCT00487318 Comparator | Jun 2007 → Oct 2010 | chronic hepatitis C virus infection | Bader, Ted, M.D. | Completed | No outcome recorded |
| Phase 3 | NCT01343888 Background | Apr 2011 → Mar 2014 | hepatitis C virus infection | Boehringer Ingelheim | Completed | Met primary |
| Phase 4 | NCT01264367 Comparator | Dec 2008 → Aug 2013 | chronic hepatitis B virus infection | Bukwang Pharmaceutical | Completed | No outcome recorded |
| Phase 4 | NCT00611819 Comparator | Nov 2005 → Apr 2008 | chronic hepatitis C virus infection, coinfection | University of Valencia | Unknown | No outcome recorded |
| — | NCT01083251 Comparator | Mar 2010 → Feb 2012 | chronic hepatitis B virus infection | Ziv Hospital | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-04-13 | Merck Sharp & Dohme LLC | Merck’s ZEPATIER™ (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial merck.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 28 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peginterferon | “Peginterferon 180 μg single dose S.C.” NCT02781753 ↗ |
| Known as | PEG-IFNα-2a | “Peginterferon (PegIFNα-2a) One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.” NCT02216045 ↗1“followed by PEG-IFNα-2a and ribavirin at standard doses and durations” PMID 23396509 ↗ Feb 2013 |
| Known as | PegIFN | “pegylated interferon (PegIFN) in patients who had previously failed a standard course of PegIFN/ribavirin (RBV) therapy.” PMID 26733671 ↗ Jan 20161“Ribavirin improves treatment response to pegylated-interferon (PEG-IFN) in chronic hepatitis C” PMID 23396509 ↗ Feb 2013 |
| Known as | peginterferon alfa 2a | “All patients will receive the standard recommended doses of peginterferon alfa 2a (180 mcg sc weekly) and ribavirin” NCT00718172 ↗ |
| Known as | pegylated interferon α-2a | “Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.” PMID 25710287 ↗ Mar 2015 |
| Known as | Pegylated Interferon-alpha | “A Phase III, Randomised, Double-blind and Placebo-controlled Study of Once Daily BI 201335 120 mg for 12 or 24 Weeks or BI 201335 240 mg for 12 Weeks in Combination With...” NCT01343888 ↗ |
| Modality | Protein / enzyme biologic | “pegylated interferon alpha-2a” PMID 29638206 ↗ Apr 2018 |
| Route | Subcutaneous | “pegInterferon, 180ug SQ/wk” NCT00249574 ↗ |